Sunday, 20 September 2026European Markets

MAUNA KEA TECH Stock Bullish By 9% So Far On Thursday

Loading stream...

(vianews) - shares of mauna kea tech (cac 40: mkea.pa) rose 9.67% to €0.64 at 14:00 est on thursday, following the last session's downward trend. cac 40 is sliding 0.48% to €7,289.82, after two successive sessions in a row of losses. this seems, so far, a somewhat bearish trend trading session today.

mauna kea tech's last close was €0.58, 41.31% below its 52-week high of €0.99.

about mauna kea tech

mauna kea technologies sa develops and markets medical devices in europe, the middle east, africa, the united states, latin america, and asia. the company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. its flagship product is cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. the company was incorporated in 2000 and is headquartered in paris, france.

earnings per share

as for profitability, mauna kea tech has a trailing twelve months eps of €-0.418.

volatility

mauna kea tech's last week, last month's, and last quarter's current intraday variation average was a negative 0.11%, a negative 0.80%, and a positive 3.15%.

mauna kea tech's highest amplitude of average volatility was 2.44% (last week), 2.43% (last month), and 3.15% (last quarter).

volume

today's last reported volume for mauna kea tech is 694699 which is 102.78% above its average volume of 342584.

more news about mauna kea tech (mkea.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com